Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-035/00
A61M-005/142
A61K-031/135
A61K-031/17
A61K-031/192
A61K-031/27
A61K-031/4164
A61K-031/42
A61K-031/428
A61K-031/435
A61K-031/4436
A61K-031/445
A61K-031/47
A61K-031/498
A61K-031/505
A61K-031/55
A61K-031/704
A61M-037/00
A61N-001/30
A61K-031/137
A61K-031/155
A61K-031/165
A61K-031/415
A61K-031/4439
A61K-031/473
A61K-031/4965
A61K-031/7072
A61K-031/708
A61K-009/00
A61K-009/70
A61K-031/4468
A61M-039/22
A61K-031/04
A61K-031/13
A61K-031/18
A61K-031/195
A61K-031/198
A61K-031/216
A61K-031/404
A61K-031/405
A61K-031/4168
A61K-031/421
A61K-031/4453
A61K-031/4458
A61K-031/465
A61K-031/485
A61K-031/4985
출원번호
US-0494392
(2017-04-21)
등록번호
US-10258738
(2019-04-16)
발명자
/ 주소
DiPierro, Guy
Giannos, Steven A.
출원인 / 주소
Chrono Therapeutics Inc.
대리인 / 주소
Shay Glenn LLP
인용정보
피인용 횟수 :
0인용 특허 :
208
초록▼
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and t
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.
대표청구항▼
1. A method for treating a human with Parkinson's disease comprising: delivering an active pharmaceutical ingredient (API) for treating Parkinson's disease, symptoms associated with Parkinson's disease, or symptoms associated with treatments for Parkinson's disease dissolved in a solvent to a skin-i
1. A method for treating a human with Parkinson's disease comprising: delivering an active pharmaceutical ingredient (API) for treating Parkinson's disease, symptoms associated with Parkinson's disease, or symptoms associated with treatments for Parkinson's disease dissolved in a solvent to a skin-interface membrane of a transdermal drug delivery device coupled to a skin of the human;absorbing the active pharmaceutical ingredient from the skin-interface membrane transdermally into the human; andmoving solvent from the skin-interface membrane through an evaporation channel of the transdermal drug delivery device. 2. The method of claim 1, wherein the API comprises one or more of the following: dopamine precursors, dopa decarboxylase inhibitors, Levodopa/carbidopa mixtures, Levodopa/carbidopa/entacapone mixtures, Levodopa/benserazide mixtures, dopamine agonists, anticholinergics, MAO-B inhibitors, COMT inhibitors, dopaminergic agonists, Ampakines Istradefylline (KW-6002), S-(−)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923), Sarizotan, bornaprine, budipine, ethopropazine, lazabemide, memantine, modafinil, talampanel, altinicline, brasofensine, safinamide, droxidopa, quinagolide, terguride, riluzole, talipexole, piroheptine, bifeprunox, spheramine, sumanirole, lisuride hydrogen maleateor, and orphenadrine. 3. The method of claim 1, wherein the API comprises levodopa. 4. The method of claim 3, wherein the API includes a Levodopa/carbidopa mixture, Levodopa/carbidopa/entacapone mixture, or Levodopa/benserazide mixture. 5. The method of claim 1, wherein the API comprises one or more of the following: Carbidopa, bromocriptine, pergolide, pramipexole, rotigotine, ropinirole, cabergoline, apomorphine, lisuride, piribedil, selegiline, Amantadine, memantine, and safinamide. 6. The method of claim 1, wherein the method further includes moving solvent from the skin-interface membrane into a solvent removal element, and wherein the solvent removal element comprises a desiccant, absorbent material, or hydrophilic material. 7. The method of claim 1, wherein delivering the API dissolved in the solvent to the skin-interface membrane of the transdermal drug delivery device coupled to the human includes delivering the API at a time, rate, sequence and/or cycle that is synchronized with a biological rhythm of the human. 8. The method of claim 1, wherein delivering the API dissolved in the solvent to the skin-interface membrane of the transdermal drug delivery device coupled to the human includes delivering the API at a time, rate, sequence and/or cycle that is selected to reduce dyskinesia in the human. 9. The method of claim 1, further comprising: repeating the delivering, absorbing and moving steps to modulate and control dosing to create a consistently therapeutically effective blood plasma concentration of the active pharmaceutical ingredient in the human. 10. The method of claim 1, further comprising: repeating the delivering, absorbing and moving steps to modulate and control dosing to create a plurality of active pharmaceutical ingredient blood plasma concentration peaks and troughs in the human. 11. The method of claim 2, wherein the API further comprises levodopa. 12. The method of claim 10, wherein the API includes levodopa and the peaks and troughs of the blood plasma concentration of levodopa are between about 1.4 to about 2.0 μg/ml. 13. The method of claim 1, wherein the API is for a purpose of treating dyskinesia. 14. The method of claim 1, further comprising: removing the transdermal drug delivery device after contacting the skin for greater than 24 hours. 15. The method of claim 1, wherein delivering the API dissolved in the solvent to the skin-interface membrane of the transdermal drug delivery device coupled to the skin of the human is performed immediately before the human wakes up. 16. The method of claim 1, wherein the transdermal drug delivery device includes a reservoir with the API dissolved in the solvent and further comprising: moving a portion of the API dissolved in the solvent from the reservoir to the skin-interface membrane. 17. The method of claim 1, wherein delivering the API dissolved in the solvent to the skin-interface membrane of the transdermal drug delivery device coupled to the skin of the human begins during a one hour period immediately prior to the human's waking to transdermally administer the API to the human. 18. The method of claim 1, wherein the delivery step comprises delivering a first dosage of API to the human to raise the human's blood plasma concentration of API from a first level to a second level higher than the first level. 19. The method of claim 18 wherein the first dosage is delivered while the human is asleep. 20. The method of claim 18, wherein delivering the first dosage of API to the human is at a time around 7:30 a.m. to 10:00 a.m. 21. The method of claim 18, wherein delivering the first dosage of API to the human is at a time around 10:00 a.m. to 12:00 p.m. 22. The method of claim 18, wherein the delivery step further comprises reducing or stopping delivery of API to the human to reduce the human's blood plasma concentration of API from the second level to a third level lower than the second level, then delivering a second dosage of API to the human to increase the human's blood plasma concentration of API from the third level to a fourth level higher than the third level. 23. The method of claim 22, wherein the second dosage of API to the human is at a time around 1:00 p.m. to about 3:00 p.m. 24. The method of claim 22, wherein the second dosage of API to the human is at a time around 3:00 p.m. to about 5:00 p.m. 25. The method of claim 22, wherein the delivery step further comprises reducing or stopping delivery of API to the human to reduce the human's blood plasma concentration of API from the fourth level to a fifth level lower than the fourth level, then delivering a third dosage of API to the human to increase the human's blood plasma concentration of API from the fifth level to a sixth level higher than the fifth level. 26. The method of claim 25, wherein the third dosage of API to the human is at a time around 6:00 p.m. to about 8:00 p.m. 27. The method of claim 25, wherein the API comprises Levodopa.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (208)
Lee Eun S. (Redwood City CA) Goetz Victor (Philadelphia PA), Abusable substance dosage form having reduced abuse potential.
Carroll Gary T. (Boulder CO) Pilmanis George J. (Boulder CO) Stinton Vincent D. (Littleton CO), Adaptable electronic monitoring and identification system.
DiPierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
DiPierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Dipierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Kanios, David P.; Hartwig, Rod; Mantelle, Juan A.; Houze, David W., Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systems.
Nagy Christa F. (Wyckoff NJ) Quick Timothy W. (Clifton NJ) Shapiro Stanley S. (Livingston NJ), Compositions of retinoic acids and tocopherol for prevention of dermatitis.
Hall Bonnie J. (Mason OH) Baur Julie A. (Fairfield OH) Deckner George E. (Cincinnati OH), Dermatological compositions and method of treatment of skin lesions therewith using benzoyl peroxide and tocopherol este.
Fallon Renee A. (Sunnyvale CA) Wilson Donald R. (San Francisco CA), Device for administering drug transdermally which provides an initial pulse of drug.
Lattin Gary A. (Forest Lake MN) Dickson Dale A. (Fridley MN) Grace Michael J. (Coon Rapids MN), Electrotransport agent delivery device having a disposable component and a removable liner.
Morita,Toshio; Inoue,Hitoshi; Nishimura,Kunio; Suhara,Yutaka; Ohshima,Satoshi; Yumura,Motoo, Fine carbon fiber, method for producing the same and electrically conducting material comprising the fine carbon fiber.
Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
Orr,Kevin H.; Mankaruse,George S.; Asaria,Ali, Handheld electronic device including vibrator having different vibration intensities and method for vibrating a handheld electronic device.
Klug Reja B. (30 Bay Dr. SE. Fort Walton Beach FL 32548) Ford Richard D. (117 Lake Lorraine Cir. Shalimar FL 32579) Jamison Keith A. (137 Indian Bayou Dr. Destin FL 32541) Stearns Ronald E. (2 Caswel, High energy coaxial cable for use in pulsed high energy systems.
Behar Albert (Reston VA) Behar Orna (Reston VA) Frederiksen Lee W. (McLean VA) Howard-Link Donald A. (Columbia MD) Timmerman Catherine (Washington DC), Human behavior modification which establishes and generates a user adaptive withdrawal schedule.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Medicament delivery device having an electronic circuit system.
Rose Jed E. (907 Kimball Dr. Durham NC 27705) Jarvik Murray E. (2001 Georgina Avenue Santa Monica CA 90402) Rose Karce D. (4050 W. Soda Rock Dr. Healdsburg CA 95448), Method and apparatus for aiding in the reduction of incidence of tobacco smoking.
Rose Jed E. (Venice CA) Jarvik Murray E. (Santa Monica CA) Rose Karce D. (Healdsburg CA), Method and apparatus for aiding in the reduction of incidence of tobacco smoking.
Segel Joseph M. ; Samuelson Michael H., Method and system for stopping or modifying undesirable health-related behavior habits or maintaining desirable health-.
Cormier Michel J. N. (Palo Alto CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA) Marty Jean P. (Sceaux FRX), Method for reducing sensitization or irritation in transdermal drug delivery and means therefor.
Majeed, Muhammed; Badmaev, Vladimir; Bammi, Rajinder Kumar; Prakash, Subbalakshmi; Natarajan, Sankaran, Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives.
Caldwell William Scott ; Dull Gary Maurice ; Bencherif Merouane ; Lippiello Patrick Michael, Methods of treating central nervous system disorders with aryl substituted olefinic amine compounds.
Dull Gary Maurice ; Wagner Jared Miller ; Caldwell William Scott ; Miller Craig Harrison ; Schmitt Jeffrey Daniel ; Bhatti Balwinder Singh ; Hadimani Srishailkumar Basawannappa, Pharmaceutical compositions and methods for use.
Gary Maurice Dull ; Craig Harrison Miller ; William Scott Caldwell ; Srishailkumar Basawannappa Hadimani, Pharmaceutical compositions and methods for use.
Peter Anthony Crooks ; Haeil Park KR; Balwinder Singh Bhatti ; William Scott Caldwell ; Gary Maurice Dull, Pharmaceutical compositions and methods for use.
Harpal S. Kumar GB; Paul Johnson GB; Michael D. Llewellyn GB; William J. Mullarkey GB; William New, Jr. ; Laurence J. Nicolson GB; William G. O'Brien GB; John D. Place GB; Peter M. Relph GB, Portable remote patient telemonitoring system.
Pete Ferguson GB; Harpal Kumar GB; Graham Lay GB; Mike Llewellyn GB; John D. Place GB, Portable remote patient telemonitoring system using a memory card or smart card.
Roberts Josephine A. (7509 Ben Avon Rd. Bethesda MD 20817) Burwell Jephthae W. (3119 Adams Mill Rd. ; NW. Washington DC 20010), Positive-pressure ventilator system with controlled access for nebulizer component servicing.
Amkraut Alfred (Palo Alto CA) Shaw Jane E. (Atherton CA), Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug.
Wong Patrick S. L. ; Dong Liang-Chang ; Edgren David E. ; Theeuwes Felix ; Gardner Phyllis I. ; Jao Francisco ; Wan Jason J., Prolonged release active agent dosage form adapted for gastric retention.
Ledger Philip W. (Mountain View CA) Cormier Michel J. (Mountain View CA) Amkraut Alfred (Palo Alto CA), Reduction or prevention of sensitization to drugs.
Cormier Michel J-N (Mountain View CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA), Reduction or prevention of skin irritation by drugs.
Cormier Michel (Mountain View CA) Amkraut Alfred (Palo Alto CA) Ledger Philip W. (Bedford GBX), Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensiti.
Fern Ove B. (Helsingborg SEX) Helgertz Stig K. A. (Helsingborg SEX) Ohlsson Corfitz B. I. (Helsingborg SEX), Smoking substitutes for nasal administration-I.
Osborne James L. (Mountain View CA) Nelson Melinda (Sunnyvale CA) Enscore David J. (Saratoga CA) Yum Su I. (Los Altos CA) Gale Robert M. (Los Altos CA), Subsaturated nicotine transdermal therapeutic system.
Walker, Jay S.; Jorasch, James A.; Nee, Jr., Patrick W.; Fincham, Carson C. K.; Walker, Evan; Bean, David; Maniam, Rajivan, Systems and methods for improved health care compliance.
Currie, John F.; Paranjape, Makarand; Peck, Carl C.; White, Robert; Schneider, Thomas W., Systems and methods for monitoring health and delivering drugs transdermally.
Gale, Robert M.; Stein, Thomas M.; Audett, Jay; Stepic, Jane; Phipps, Joseph B.; Cormier, Michel J. N., Transdermal analgesic systems with reduced abuse potential.
Haak Ronald P. (Menlo Park CA) Theeuwes Felix (Los Altos Hills CA) Gyory J. Richard (San Jose CA) Lattin Gary A. (Forest Lake MN), Transdermal delivery device.
Bello Gastone P. (Monmouth Beach NJ) Lyle John W. (Belmar NJ) Johnson Donald A. (Sea Girt NJ), Transdermal drug delivery device and method for its manufacture.
Fallon Renee A. (Sunnyvale CA) Venkatraman Subbu S. (Palo Alto CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset.
Venktrama Subbu S. (Palo Alto CA) Fallon Renee A. (Sunnyvale CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset.
Govil Sharad K. (Plantation FL) Rudnic Edward M. (Boca Raton FL) Sterner Dale G. (Pembroke Pines FL), Transdermal nitroglycerin patch with penetration enhancers.
Hille,Thomas; Deurer,Lothar, Transdermal therapeutic system comprising a reservoir type pressure sensitive adhesive layer and a back layer with uni-directional resilience.
Müller, Walter; Leonhard, Johannes, Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Kang, Sewon; Fisher, Gary J.; Voorhees, John J., Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor.
Heiber Werner (Bedford Hills NY) Andriola Robert (Putnam Valley NY) Williams Paul (Fairlawn NJ) Ebert Charles (Redwood City CA), User-activated transdermal therapeutic system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.